<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541409</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA02672</org_study_id>
    <secondary_id>R01DA026727</secondary_id>
    <nct_id>NCT02541409</nct_id>
  </id_info>
  <brief_title>Directly Observed Therapy for HCV in Chennai, India</brief_title>
  <acronym>C-DOT</acronym>
  <official_title>Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>YR Gaitonde Centre for AIDS Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24&#xD;
      weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited&#xD;
      setting. The investigators will compare treatment completion rates among 50 persons&#xD;
      chronically infected with HCV who will be randomized to receive either 1) 12 weeks of&#xD;
      sofosbuvir (SOF) + ribavirin (RBV) + pegylated interferon alfa-2a (PEG); or 2) 24 weeks of&#xD;
      SOF + RBV. Treatment will be delivered daily by field workers at a location of a participants&#xD;
      choosing. Secondary objectives are 1) To compare the efficacy of SOF+RBV with or without PEG&#xD;
      as measured by the proportion of subjects with sustained viral response at 12 weeks after&#xD;
      discontinuation of therapy (SVR12); 2) To evaluate the safety and tolerability of SOF+RBV&#xD;
      with or without PEG; 3) To assess the impact of SVR12 on insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-blinded randomized clinical trial with 50 participants randomized at a 1:1&#xD;
      allocation ratio to one of two treatment arms.&#xD;
&#xD;
      Arm 1: Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin&#xD;
      (800mg/daily) for 12 weeks&#xD;
&#xD;
      Arm 2: Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
&#xD;
      Pegylated-interferon alfa-2a (PEG) will be delivered subcutaneously once weekly. Sofosbuvir&#xD;
      (SOF) and ribavirin (RBV) will be taken orally once daily for the entire study period.&#xD;
&#xD;
      The study will take place at the YR Gaitonde Centre for AIDS Research and Education&#xD;
      (YRGCARE). YRG CARE is a non-profit medical and research institution in Chennai. YRGCARE&#xD;
      Medical Centre provides medical care for more than 18,000 persons with HIV disease. Currently&#xD;
      more than 8000 persons are receiving highly active antiretroviral therapy at the center.&#xD;
&#xD;
      Participants will be recruited from the YR Gaitonde Centre for Substance Abuse Research&#xD;
      (YRGCSAR), which is affiliated with YRGCARE. The investigators will primarily recruit&#xD;
      subjects from a cohort study of current and former people who inject drugs (PWID) that is&#xD;
      ongoing at the same center. Eligible participants will be randomized to one of the two&#xD;
      treatment arms after providing written informed consent. Treatment will be delivered directly&#xD;
      to participants daily by field workers at a location of the participants choosing.&#xD;
      Participants will be asked to visit the study clinic every four weeks during treatment and 12&#xD;
      weeks after completing treatment for additional study procedures. In addition, participants&#xD;
      in Arm 1 will be asked to visit the clinic every week to receive their PEG injection.&#xD;
&#xD;
      The primary outcome is treatment completion. Secondary outcomes include SVR12, safety and&#xD;
      tolerability and insulin resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV Treatment Completion</measure>
    <time_frame>12 weeks from baseline for SOF+PEG+RBV and 24 weeks from baselne for SOF+RBV</time_frame>
    <description>The percentage of subjects that complete their course of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response (SVR)</measure>
    <time_frame>24 weeks from baseline for SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV</time_frame>
    <description>The percentage of participants who achieve SVR as assessed by undetectable HCV RNA measured 12 weeks after treatment completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>24 weeks from baseline SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV</time_frame>
    <description>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance</measure>
    <time_frame>Difference from entry to 24 weeks for SOF+PEG+RBV and difference from entry to 36 weeks for SOF+RBV</time_frame>
    <description>Change in insulin resistance while on treatment by the homeostasis model assessment - insulin resistance (HOMA-IR). HOMA-IR is calculated according to the formula (fasting insulin (microU/L)+fasting glucose (nmol/L)/22.5. Fasting insulin and glucose measurements are obtained using whole blood.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Direct acting antiviral agent used for the treatment of hepatitis C</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <arm_group_label>SOF+RBV</arm_group_label>
    <other_name>Sovaldi, Hepcvir, MyHep, Hepcinat, Resof, SoviHep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alfa-2a</intervention_name>
    <description>Antiviral agent used for the treatment of hepatitis C</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <other_name>Pegasys, Taspiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <arm_group_label>SOF+RBV</arm_group_label>
    <other_name>Rebetol, Copegus, Univirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing/able to provide consent&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
          3. Chronic HCV (HCV RNA positive)&#xD;
&#xD;
          4. Resident of Chennai and can provide locator information&#xD;
&#xD;
          5. If co-infected with HIV, must have CD4 (Cluster of Differentation 4) &gt; 350 cells/mm3&#xD;
             and either: 1) ART naïve or 2) if on ART be on a tenofovir-containing regimen. If a&#xD;
             participant's CD4 drops below 350 cells/μl (threshold for treatment in India), will&#xD;
             have to initiate a tenofovir-containing regimen (current standard of care).&#xD;
&#xD;
          6. Participants must have the following at screening:&#xD;
&#xD;
               1. Alanine Aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN)&#xD;
&#xD;
               2. Aspartate Aminotransferase (AST) ≤ 10 x ULN&#xD;
&#xD;
               3. Hemoglobin ≥ 12 g/dl for males and 11 g/dl for females&#xD;
&#xD;
               4. International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known&#xD;
                  hemophilia or is stable on an anticoagulant regimen affecting INR&#xD;
&#xD;
               5. Albumin ≥ 3 g/dl&#xD;
&#xD;
               6. Direct bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               7. Creatinine clearance ≥ 60 ml/min (Cockgroft-Gault Equation)&#xD;
&#xD;
               8. Alpha fetoprotein &lt; 50 ng/ml&#xD;
&#xD;
               9. Absolute neutrophil count (ANC) ≥ 1,500/μL&#xD;
&#xD;
              10. Platelets ≥ 90,000/μL&#xD;
&#xD;
              11. Thyroid stimulating hormone (TSH) ≤ ULN&#xD;
&#xD;
          7. A female subject is eligible if it is confirmed that she is:&#xD;
&#xD;
               1. Not pregnant or nursing&#xD;
&#xD;
               2. Of non-childbearing potential (i.e., women who have had hysterectomy, have both&#xD;
                  ovaries removed or medically documented ovarian failure, or are postmenopausal&#xD;
                  women &gt; 50 years of age with cessation (for ≥12 months) of previously occurring&#xD;
                  menses&#xD;
&#xD;
               3. Of childbearing potential and negative urine pregnancy test prior to&#xD;
                  randomization and agree to one of the following from 3 weeks prior to&#xD;
                  Baseline/Day 1 until 6 months after the last dose of RBV.&#xD;
&#xD;
                    -  Complete abstinence from intercourse.&#xD;
&#xD;
             Or&#xD;
&#xD;
             • Consistent use of approved methods of birth control in addition to a male partner&#xD;
             who correctly uses a condom from 3 weeks prior to Baseline/Day 1 until 6 months after&#xD;
             the last dose of RBV.&#xD;
&#xD;
          8. Male participants must agree to consistently and correctly use a condom. If their&#xD;
             female partner is of childbearing potential, their partner must agree to use one of&#xD;
             the study approved non-hormonal methods of birth control or a hormone-containing&#xD;
             contraceptive, from the date of screening until 7 months after their last dose of RBV&#xD;
&#xD;
          9. Male participants must agree to refrain from sperm donation for at least 7 months&#xD;
             after the last dose of RBV.&#xD;
&#xD;
         10. Of generally good health as determined by the investigator.&#xD;
&#xD;
         11. Able to comply with the dosing instructions for study drug administration and willing&#xD;
             to complete the study schedule of assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant/nursing female or male with pregnant/nursing female partner.&#xD;
&#xD;
          2. Current or prior history of clinical hepatic decompensation (e.g., ascites,&#xD;
             encephalopathy or variceal hemorrhage, MELD&lt;12)&#xD;
&#xD;
          3. Prior hepatitis C treatment&#xD;
&#xD;
          4. Infection with hepatitis B virus&#xD;
&#xD;
          5. Chronic use of systematically administered immunosuppressive agents (e.g., prednisone&#xD;
             equivalent &gt;10 mg/day)&#xD;
&#xD;
          6. Use of any prohibited concomitant medications within 28 days of the Baseline/Day 1&#xD;
             visit.&#xD;
&#xD;
          7. Contraindications to RBV therapy or PEG/RBV&#xD;
&#xD;
          8. Known hypersensitivity to RBV or PEG, the metabolites or formulation excipients&#xD;
&#xD;
          9. Additional exclusion criteria related to Aim 1 regimen&#xD;
&#xD;
               1. Pre-existing significant psychiatric condition(s) including severe depression,&#xD;
                  severe bipolar disorder and schizophrenia. Other psychiatric disorders are&#xD;
                  permitted if the condition is well controlled with a stable treatment regimen for&#xD;
                  ≥ 1 year from screening.&#xD;
&#xD;
               2. Presence of autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid&#xD;
                  arthritis, sarcoidosis).&#xD;
&#xD;
               3. History of clinical significant retinal disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil S Solomon, MBBS, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>YR Gaitonde Centre for AIDS Research and Education</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <results_first_submitted>April 27, 2020</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2021</results_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>directly observed therapy</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>ribavirin</keyword>
  <keyword>pegylated interferon</keyword>
  <keyword>resource-limited setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SOF+PEG+RBV</title>
          <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
        </group>
        <group group_id="P2">
          <title>SOF+RBV</title>
          <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SOF+PEG+RBV</title>
          <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
        </group>
        <group group_id="B2">
          <title>SOF+RBV</title>
          <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="41" upper_limit="50"/>
                    <measurement group_id="B2" value="46" lower_limit="44" upper_limit="47"/>
                    <measurement group_id="B3" value="46" lower_limit="42" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype 3a</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype 1a</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype 6n</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime Injection Drug Use: Heroin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime Injection Drug Use: Sedatives</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime Injection Drug Use: Other Opioids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injection Drug use in Prior 6 Months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NonInjection Drug Use in Prior 6 Months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marijuana Use in Prior 6 Months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No Alcohol Use in Prior 6 Months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use in Prior 6 Months: 1-4 Drinks Daily</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use in Prior 6 Months: &gt;5 Drinks Daily</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use: No/Mild Alcohol Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use: Harmful/Hazardous Alcohol Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use: Alcohol Dependence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HCV Treatment Completion</title>
        <description>The percentage of subjects that complete their course of treatment</description>
        <time_frame>12 weeks from baseline for SOF+PEG+RBV and 24 weeks from baselne for SOF+RBV</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>HCV Treatment Completion</title>
          <description>The percentage of subjects that complete their course of treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response (SVR)</title>
        <description>The percentage of participants who achieve SVR as assessed by undetectable HCV RNA measured 12 weeks after treatment completion</description>
        <time_frame>24 weeks from baseline for SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR)</title>
          <description>The percentage of participants who achieve SVR as assessed by undetectable HCV RNA measured 12 weeks after treatment completion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</description>
        <time_frame>24 weeks from baseline SOF+PEG+RBV and 36 weeks from baseline for SOF+RBV</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance</title>
        <description>Change in insulin resistance while on treatment by the homeostasis model assessment - insulin resistance (HOMA-IR). HOMA-IR is calculated according to the formula (fasting insulin (microU/L)+fasting glucose (nmol/L)/22.5. Fasting insulin and glucose measurements are obtained using whole blood.</description>
        <time_frame>Difference from entry to 24 weeks for SOF+PEG+RBV and difference from entry to 36 weeks for SOF+RBV</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SOF+PEG+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
          <group group_id="O2">
            <title>SOF+RBV</title>
            <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance</title>
          <description>Change in insulin resistance while on treatment by the homeostasis model assessment - insulin resistance (HOMA-IR). HOMA-IR is calculated according to the formula (fasting insulin (microU/L)+fasting glucose (nmol/L)/22.5. Fasting insulin and glucose measurements are obtained using whole blood.</description>
          <units>HOMA-IR</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-0.1" upper_limit="9.1"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.3" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SOF+PEG+RBV</title>
          <description>Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Pegylated Interferon alfa-2a: Antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
        </group>
        <group group_id="E2">
          <title>SOF+RBV</title>
          <description>Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks&#xD;
Sofosbuvir: Direct acting antiviral agent used for the treatment of hepatitis C&#xD;
Ribavirin: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shruti Mehta</name_or_title>
      <organization>Johns Hopkins University Bloomberg School of Public Health</organization>
      <phone>443-287-3837</phone>
      <email>smehta@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

